Drug Target Review2025-10-10T13:30:37
Scientists have developed a new gene therapy that reversed symptoms of SYNGAP1-related brain disorders in mice, which could lead to new treatments for this group of neurological conditions.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-09-10T08:41:00Z
Sponsored by DNA Genotek Inc.
2026-07-08T07:58:00
Contributor Dr Nick Lynch, Dr Raminderpal Singh
2023-09-27T13:56:39
Sponsored by Euretos
2026-08-24T08:43:00
Author Dr Dana Watt
2025-05-14T14:30:00
Sponsored by Abzena
2026-08-11T07:02:00
Contributor Professor Joseph C. Wu, Drug Target Review
2026-07-23T06:20:00
Contributor Laura Lotfi, Drug Target Review
Site powered by Webvision Cloud